The United States has questioned vaccine data …

U.S. health officials believe AstraZeneca may have provided outdated information on the effectiveness of its coronavirus vaccine. On Monday, the Anglo-Swedish pharmaceutical company published the results of a massive study in which it found that the drug’s effectiveness was 79%. The US National Institute of Allergy and Infectious Diseases (NIAID) requested that I provide updated data as soon as possible to authorize emergency use of the vaccine in the United States. The order is given as part of the commercial fight raised between the countries and the laboratories

According to a statement released by NIAID, the Data and Security Oversight Council (DSMB) – made up of a group of independent experts who advise the government of President Joe Biden- expressed concern about the timeliness of information provided by AstraZeneca on the clinical trial of its vaccine.

“The DSMB has expressed concern that AstraZeneca may have included outdated information from this trial, which may have provided an incomplete view of the efficacy data.”said the NIAID statement.

“We urge the company (AstraZeneca) to work with the DSMB to review the efficacy data and ensure that these more accurate and up-to-date efficacy figures are released as soon as possible.he adds.

The NIAID text concludes by stating that the authorization and guidelines for the use of the vaccine in the United States “will be determined by the Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention. After a comprehensive review of given by independent advisory committees. “

NIAID statement released hours later White House called AstraZeneca study result “encouraging”. Government Headquarters spokeswoman Jen Psaki confirmed that if the regulator gives AstraZeneca the green light, the vaccine “will be integrated into the process of distributing” doses in the country, as well as those already approved by Pfizer, Moderna and Johnson and Johnson.

The United States has yet to approve emergency use of the AstraZeneca vaccine., although last year she negotiated the purchase of 300 million doses of this preparation.

On Monday, AstraZeneca published the results of a clinical trial that brought together more than 32,000 volunteers in the United States, Peru and Chile that showed the vaccine to be 79% effective in preventing symptomatic covid-19 and avoid forms of serious illness. In addition, the laboratory confirmed that the vaccine did not increase the risk of blood clots.

European countries had temporarily suspended vaccination with the drug AstraZeneca after detecting cases of thrombi in people who had been inoculated. The European Medicines Agency (EMA) has claimed the vaccine is “safe and effective” and vaccination campaigns have resumed.